Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2001

View Archived Issues

Spotlight on cell therapy for Parkinson's disease

NeuGene antisense compound effective against calicivirus

Encouraging preliminary results for vagus nerve stimulation in the treatment of AD

Phase II/III trials evaluate Apomate for detection of early response to chemotherapy

BTG creates new company to develop ketone body technology

deCODE maps gene linked to rheumatoid arthritis

Epimmune and Bavarian Nordic collaborate to develop HIV vaccines

PhotoCure's Metvix PDT receives European approval

New phase III trial initiated for alicaforsen in Crohn's disease

CeNeS sells chemical library of ion channel blockers to Scion

Tubulin polymerization inhibitors active against MDR tumors identified by Abbott

First approval obtained for new BPH therapeutic from GSK

Teveten HCT receives marketing approval in U.S.

LDP-392 more effective than PAF antagonists or 5-LO inhibitors in models of inflammation

Preapproval manufacturing inspection for Imavist successful

Amerimmune's novel HIV treatment completes phase Ia trial

MBI-594AN gives positive results in acne trial

Enrollment completed for eflornithine phase III pivotal trial

COBALT therapy produces dramatic antitumor effects in animals

Novel compositions and methods for gene therapy described in recent patent

Osteogenesis-promoting thiophene derivatives developed at Takeda

Potential new naturally produced anti-HIV agents with CCR5-antagonist activity

Nippon Shinyaku's new analgesics target the nociceptin receptor

Sodium channel blockers and use in epilepsy, pain, etc.

Darwin Discovery patents series of PDE7 inhibitors

Broad-spectrum antifungal agents reported by Aventis

MS&D designs compounds acting as selective 5-HT2A receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...